Clovis Oncology (CLVS) Tops Q1 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. IVBIY
9. SPY
10. FIX

Go back to Clovis Oncology (CLVS) Tops Q1 EPS by 11c

Clovis Oncology Announces First Quarter 2019 Operating Results

May 7, 2019 8:00 AM EDT

$33.1M in Rubraca® (rucaparib) global sales for the first quarter of 2018 Updated data on 52 patients with BRCA-mutant mCRPC provided to FDA; RECIST response rate highly consistent with that shown at ESMO 2018 Targeting late 2019 for supplemental NDA filing for BRCA-mutant advanced prostate cancer; data update expected at Fall 2019 medical meeting Clovis-sponsored combination studies of lucitanib with rucaparib and Bristol-Myers Squibbs Opdivo expected to begin in mid-2019; Entered into non-dilutive clinical trial financing up to $175M to fund quarterly expenses... More